stars 1 stars 2 stars 3

Dauntless Pharmaceuticals, Inc. develops specialty pharmaceutical drugs via a one-asset, one-company model that is structured to facilitate operational efficiencies. Dauntless 1, its first asset company, was formed to develop DP1038, a therapeutic agent for the treatment of acromegaly and neuroendocrine tumors. Dauntless Pharmaceuticals, started in 2015, has raised committed capital of $32 million from its founding investor, Sofinnova, along with Canaan Partners who led the most recent financing. The funds are dedicated to the advancement of the first asset, DP1038, and an undisclosed second asset.

Dauntless Studios Questions

The Dauntless Studios annual revenue was $10.4 million in 2026.

1 people are employed at Dauntless Studios.

Dauntless Studios is based in San Diego, California.

The NAICS codes for Dauntless Studios are [51, 51211, 512, 5121, 512110].

The SIC codes for Dauntless Studios are [781, 78].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users